The global optic nerve disorder treatment market accounted for $3,372.46 million in 2021, and is expected to reach $5,247.82 million by 2031, registering a CAGR of 4.5% from 2022 to 2031.
The optic nerve of the eye is the second cranial nerve, which helps transmit sensory information to the brain for vision. This nerve develops from optic vesicle of the forebrain during fetal development. Damage to the optic nerve or its pathways that lead to the brain may result in the loss of vision.
Different types of optic nerve disorders are prevalent across the globe such as glaucoma, optic nerve atrophy, optic neuritis and others. Most of these disorders are symptomatically treated. The treatments may not improve vision, but they can help to prevent vision loss that may occur further with the disorder.
It is estimated that optic nerve disorder treatment market is expected to experience significant market growth during the forecast period owing to the increasing geriatric population suffering from eye diseases, the launch of innovative technologies, a boost in healthcare expenditure, and higher government support. In addition, increase in investment by players in R&D and presence of robust pipeline candidates and rise in expenditure on the development of healthcare infrastructure, which further facilitate the growth of the market. However, Dearth of skilled professionals expected to impede the market growth. In contrast, surge in healthcare investments in public as well as private sectors are anticipated to provide significant growth opportunities for the optic nerve disorder treatment market.
The optic nerve disorder treatment market is segmented on the basis of treatment type, indication, distribution channel and region. Depending on treatment type, the market is classified into steroidal therapy, immunomodulators therapy and others treatment type. On the basis of indication, the market is categorized into optic neuritis, glaucoma, optic nerve atrophy and others. By distribution channel, the market is classified into hospital pharmacies, drug stores, retail pharmacies and online providers.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The report provides -A comprehensive analysis of the key players that operate in the global optic nerve disorder treatment market. The key companies profiled in the report include AbbVie Inc., Alcon Inc, Bausch Health Companies, Inc., Cipla Ltd., Mallinckrodt pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Santen Pharmaceutical Co., Ltd., Teva pharmaceutical industries ltd.
The optic nerve of the eye is the second cranial nerve, which helps transmit sensory information to the brain for vision. This nerve develops from optic vesicle of the forebrain during fetal development. Damage to the optic nerve or its pathways that lead to the brain may result in the loss of vision.
Different types of optic nerve disorders are prevalent across the globe such as glaucoma, optic nerve atrophy, optic neuritis and others. Most of these disorders are symptomatically treated. The treatments may not improve vision, but they can help to prevent vision loss that may occur further with the disorder.
It is estimated that optic nerve disorder treatment market is expected to experience significant market growth during the forecast period owing to the increasing geriatric population suffering from eye diseases, the launch of innovative technologies, a boost in healthcare expenditure, and higher government support. In addition, increase in investment by players in R&D and presence of robust pipeline candidates and rise in expenditure on the development of healthcare infrastructure, which further facilitate the growth of the market. However, Dearth of skilled professionals expected to impede the market growth. In contrast, surge in healthcare investments in public as well as private sectors are anticipated to provide significant growth opportunities for the optic nerve disorder treatment market.
The optic nerve disorder treatment market is segmented on the basis of treatment type, indication, distribution channel and region. Depending on treatment type, the market is classified into steroidal therapy, immunomodulators therapy and others treatment type. On the basis of indication, the market is categorized into optic neuritis, glaucoma, optic nerve atrophy and others. By distribution channel, the market is classified into hospital pharmacies, drug stores, retail pharmacies and online providers.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The report provides -A comprehensive analysis of the key players that operate in the global optic nerve disorder treatment market. The key companies profiled in the report include AbbVie Inc., Alcon Inc, Bausch Health Companies, Inc., Cipla Ltd., Mallinckrodt pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Santen Pharmaceutical Co., Ltd., Teva pharmaceutical industries ltd.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the optic nerve disorders treatment market analysis from 2021 to 2031 to identify the prevailing optic nerve disorders treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's Five Forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the optic nerve disorders treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global optic nerve disorders treatment market trends, key players, market segments, application areas, and market growth Strategies.
Key Market Segments
By Treatment Type
- Steroidal Therapy
- Immunomodulators therapy
By Indication
- Glaucoma
- Optic Neuritis
By Distribution Channel
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Providers
By Region
- North America
- U.S.
- Canda
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Santen Pharmaceutical Co., Ltd.
- AbbVie Inc.
- Novartis AG
- Bausch Health Companies, Inc.
- Merck & Co., Inc.
- .Aerie Pharmaceuticals, Inc.
- Cipla Ltd
- mallinckrodt pharmaceuticals
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. High bargaining power of suppliers
3.3.2. Moderate bargaining power of buyers
3.3.3. High threat of substitutes
3.3.4. High threat of new entrants
3.3.5. Moderate intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of optic nerve disorder
3.4.1.2. Growth in geriatric population
3.4.1.3. Increase in technological advancement
3.4.2. Restraints
3.4.2.1. Dearth of skilled professionals
3.4.3. Opportunities
3.4.3.1. Growth potential of emerging economies
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Steroidal Therapy
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Immunomodulators therapy
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Glaucoma
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Optic Neuritis
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Drug Stores and Retail Pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online Providers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: OPTIC NERVE DISORDERS TREATMENT MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Treatment Type
7.2.3. Market size and forecast, by Indication
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Treatment Type
7.2.5.1.3. Market size and forecast, by Indication
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canda
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Treatment Type
7.2.5.2.3. Market size and forecast, by Indication
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Treatment Type
7.2.5.3.3. Market size and forecast, by Indication
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Treatment Type
7.3.3. Market size and forecast, by Indication
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Treatment Type
7.3.5.1.3. Market size and forecast, by Indication
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Treatment Type
7.3.5.2.3. Market size and forecast, by Indication
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Treatment Type
7.3.5.3.3. Market size and forecast, by Indication
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Treatment Type
7.3.5.4.3. Market size and forecast, by Indication
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Treatment Type
7.3.5.5.3. Market size and forecast, by Indication
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Treatment Type
7.3.5.6.3. Market size and forecast, by Indication
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Treatment Type
7.4.3. Market size and forecast, by Indication
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Treatment Type
7.4.5.1.3. Market size and forecast, by Indication
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Treatment Type
7.4.5.2.3. Market size and forecast, by Indication
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Treatment Type
7.4.5.3.3. Market size and forecast, by Indication
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Treatment Type
7.4.5.4.3. Market size and forecast, by Indication
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Treatment Type
7.4.5.5.3. Market size and forecast, by Indication
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Treatment Type
7.4.5.6.3. Market size and forecast, by Indication
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Treatment Type
7.5.3. Market size and forecast, by Indication
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Treatment Type
7.5.5.1.3. Market size and forecast, by Indication
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Treatment Type
7.5.5.2.3. Market size and forecast, by Indication
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Treatment Type
7.5.5.3.3. Market size and forecast, by Indication
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Treatment Type
7.5.5.4.3. Market size and forecast, by Indication
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. Santen Pharmaceutical Co., Ltd.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. AbbVie Inc.
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Novartis AG
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Pfizer, Inc.
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Bausch Health Companies, Inc.
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Teva Pharmaceutical Industries Ltd.
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. mallinckrodt pharmaceuticals
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Merck & Co., Inc.
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. .Aerie Pharmaceuticals, Inc.
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Cipla Ltd
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
List of Tables
Table 01. Global Optic Nerve Disorders Treatment Market, by Treatment Type, 2021-2031 (Revenue, $Million)
Table 02. Optic Nerve Disorders Treatment Market for Steroidal Therapy, by Region, 2021-2031 (Revenue, $Million)
Table 03. Optic Nerve Disorders Treatment Market for Immunomodulators Therapy, by Region, 2021-2031 (Revenue, $Million)
Table 04. Optic Nerve Disorders Treatment Market for Others, by Region, 2021-2031 (Revenue, $Million)
Table 05. Global Optic Nerve Disorders Treatment Market, by Indication, 2021-2031 (Revenue, $Million)
Table 06. Optic Nerve Disorders Treatment Market for Glaucoma, by Region, 2021-2031 (Revenue, $Million)
Table 07. Optic Nerve Disorders Treatment Market for Optic Neuritis, by Region, 2021-2031 (Revenue, $Million)
Table 08. Optic Nerve Disorders Treatment Market for Others, by Region, 2021-2031 (Revenue, $Million)
Table 09. Global Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 10. Optic Nerve Disorders Treatment Market for Hospital Pharmacies, by Region, 2021-2031 (Revenue, $Million)
Table 11. Optic Nerve Disorders Treatment Market for Drug Stores and Retail Pharmacies, by Region, 2021-2031 (Revenue, $Million)
Table 12. Optic Nerve Disorders Treatment Market for Online Providers, by Region, 2021-2031 (Revenue, $Million)
Table 13. Optic Nerve Disorders Treatment Market, by Region, 2021-2031 (Revenue, $Million)
Table 14. North America Optic Nerve Disorders Treatment Market, by Treatment Type, 2021-2031 (Revenue, $Million)
Table 15. North America Optic Nerve Disorders Treatment Market, by Indication, 2021-2031 (Revenue, $Million)
Table 16. North America Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 17. North America Optic Nerve Disorders Treatment Market, by Country, 2021-2031 (Revenue, $Million)
Table 18. U.S. Optic Nerve Disorders Treatment Market, by Treatment Type, 2021-2031 (Revenue, $Million)
Table 19. U.S. Optic Nerve Disorders Treatment Market, by Indication, 2021-2031 (Revenue, $Million)
Table 20. U.S. Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 21. Canda Optic Nerve Disorders Treatment Market, by Treatment Type, 2021-2031 (Revenue, $Million)
Table 22. Canda Optic Nerve Disorders Treatment Market, by Indication, 2021-2031 (Revenue, $Million)
Table 23. Canda Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 24. Mexico Optic Nerve Disorders Treatment Market, by Treatment Type, 2021-2031 (Revenue, $Million)
Table 25. Mexico Optic Nerve Disorders Treatment Market, by Indication, 2021-2031 (Revenue, $Million)
Table 26. Mexico Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 27. Europe Optic Nerve Disorders Treatment Market, by Treatment Type, 2021-2031 (Revenue, $Million)
Table 28. Europe Optic Nerve Disorders Treatment Market, by Indication, 2021-2031 (Revenue, $Million)
Table 29. Europe Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 30. Europe Optic Nerve Disorders Treatment Market, by Country, 2021-2031 (Revenue, $Million)
Table 31. Germany Optic Nerve Disorders Treatment Market, by Treatment Type, 2021-2031 (Revenue, $Million)
Table 32. Germany Optic Nerve Disorders Treatment Market, by Indication, 2021-2031 (Revenue, $Million)
Table 33. Germany Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 34. France Optic Nerve Disorders Treatment Market, by Treatment Type, 2021-2031 (Revenue, $Million)
Table 35. France Optic Nerve Disorders Treatment Market, by Indication, 2021-2031 (Revenue, $Million)
Table 36. France Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 37. UK Optic Nerve Disorders Treatment Market, by Treatment Type, 2021-2031 (Revenue, $Million)
Table 38. UK Optic Nerve Disorders Treatment Market, by Indication, 2021-2031 (Revenue, $Million)
Table 39. UK Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 40. Italy Optic Nerve Disorders Treatment Market, by Treatment Type, 2021-2031 (Revenue, $Million)
Table 41. Italy Optic Nerve Disorders Treatment Market, by Indication, 2021-2031 (Revenue, $Million)
Table 42. Italy Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 43. Spain Optic Nerve Disorders Treatment Market, by Treatment Type, 2021-2031 (Revenue, $Million)
Table 44. Spain Optic Nerve Disorders Treatment Market, by Indication, 2021-2031 (Revenue, $Million)
Table 45. Spain Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 46. Rest of Europe Optic Nerve Disorders Treatment Market, by Treatment Type, 2021-2031 (Revenue, $Million)
Table 47. Rest of Europe Optic Nerve Disorders Treatment Market, by Indication, 2021-2031 (Revenue, $Million)
Table 48. Rest of Europe Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 49. Asia-Pacific Optic Nerve Disorders Treatment Market, by Treatment Type, 2021-2031 (Revenue, $Million)
Table 50. Asia-Pacific Optic Nerve Disorders Treatment Market, by Indication, 2021-2031 (Revenue, $Million)
Table 51. Asia-Pacific Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 52. Asia-Pacific Optic Nerve Disorders Treatment Market, by Country, 2021-2031 (Revenue, $Million)
Table 53. Japan Optic Nerve Disorders Treatment Market, by Treatment Type, 2021-2031 (Revenue, $Million)
Table 54. Japan Optic Nerve Disorders Treatment Market, by Indication, 2021-2031 (Revenue, $Million)
Table 55. Japan Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 56. China Optic Nerve Disorders Treatment Market, by Treatment Type, 2021-2031 (Revenue, $Million)
Table 57. China Optic Nerve Disorders Treatment Market, by Indication, 2021-2031 (Revenue, $Million)
Table 58. China Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 59. India Optic Nerve Disorders Treatment Market, by Treatment Type, 2021-2031 (Revenue, $Million)
Table 60. India Optic Nerve Disorders Treatment Market, by Indication, 2021-2031 (Revenue, $Million)
Table 61. India Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 62. Australia Optic Nerve Disorders Treatment Market, by Treatment Type, 2021-2031 (Revenue, $Million)
Table 63. Australia Optic Nerve Disorders Treatment Market, by Indication, 2021-2031 (Revenue, $Million)
Table 64. Australia Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 65. South Korea Optic Nerve Disorders Treatment Market, by Treatment Type, 2021-2031 (Revenue, $Million)
Table 66. South Korea Optic Nerve Disorders Treatment Market, by Indication, 2021-2031 (Revenue, $Million)
Table 67. South Korea Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 68. Rest of Asia-Pacific Optic Nerve Disorders Treatment Market, by Treatment Type, 2021-2031 (Revenue, $Million)
Table 69. Rest of Asia-Pacific Optic Nerve Disorders Treatment Market, by Indication, 2021-2031 (Revenue, $Million)
Table 70. Rest of Asia-Pacific Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 71. LAMEA Optic Nerve Disorders Treatment Market, by Treatment Type, 2021-2031 (Revenue, $Million)
Table 72. LAMEA Optic Nerve Disorders Treatment Market, by Indication, 2021-2031 (Revenue, $Million)
Table 73. LAMEA Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 74. LAMEA Optic Nerve Disorders Treatment Market, by Country, 2021-2031 (Revenue, $Million)
Table 75. Brazil Optic Nerve Disorders Treatment Market, by Treatment Type, 2021-2031 (Revenue, $Million)
Table 76. Brazil Optic Nerve Disorders Treatment Market, by Indication, 2021-2031 (Revenue, $Million)
Table 77. Brazil Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 78. Saudi Arabia Optic Nerve Disorders Treatment Market, by Treatment Type, 2021-2031 (Revenue, $Million)
Table 79. Saudi Arabia Optic Nerve Disorders Treatment Market, by Indication, 2021-2031 (Revenue, $Million)
Table 80. Saudi Arabia Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 81. South Africa Optic Nerve Disorders Treatment Market, by Treatment Type, 2021-2031 (Revenue, $Million)
Table 82. South Africa Optic Nerve Disorders Treatment Market, by Indication, 2021-2031 (Revenue, $Million)
Table 83. South Africa Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 84. Rest of LAMEA Optic Nerve Disorders Treatment Market, by Treatment Type, 2021-2031 (Revenue, $Million)
Table 85. Rest of LAMEA Optic Nerve Disorders Treatment Market, by Indication, 2021-2031 (Revenue, $Million)
Table 86. Rest of LAMEA Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 87. Santen Pharmaceutical Co. Ltd.: Key Executives
Table 88. Santen Pharmaceutical Co. Ltd.: Company Snapshot
Table 89. Santen Pharmaceutical Co. Ltd.: Product Segments
Table 90. Santen Pharmaceutical Co. Ltd.: Product Portfolio
Table 91. Santen Pharmaceutical Co. Ltd.: Key Strategies
Table 92. Abbvie Inc.: Key Executives
Table 93. Abbvie Inc.: Company Snapshot
Table 94. Abbvie Inc.: Product Segments
Table 95. Abbvie Inc.: Product Portfolio
Table 96. Abbvie Inc.: Key Strategies
Table 97. Novartis AG: Key Executives
Table 98. Novartis AG: Company Snapshot
Table 99. Novartis AG: Product Segments
Table 100. Novartis AG: Product Portfolio
Table 101. Novartis AG: Key Strategies
Table 102. Pfizer, Inc.: Key Executives
Table 103. Pfizer, Inc.: Company Snapshot
Table 104. Pfizer, Inc.: Product Segments
Table 105. Pfizer, Inc.: Product Portfolio
Table 106. Bausch Health Companies, Inc.: Key Executives
Table 107. Bausch Health Companies, Inc.: Company Snapshot
Table 108. Bausch Health Companies, Inc.: Product Segments
Table 109. Bausch Health Companies, Inc.: Product Portfolio
Table 110. Teva Pharmaceutical Industries Ltd.: Key Executives
Table 111. Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 112. Teva Pharmaceutical Industries Ltd.: Product Segments
Table 113. Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 114. Teva Pharmaceutical Industries Ltd.: Key Strategies
Table 115. Mallinckrodt Pharmaceuticals: Key Executives
Table 116. Mallinckrodt Pharmaceuticals: Company Snapshot
Table 117. Mallinckrodt Pharmaceuticals: Product Segments
Table 118. Mallinckrodt Pharmaceuticals: Product Portfolio
Table 119. Merck & Co. Inc.: Key Executives
Table 120. Merck & Co. Inc.: Company Snapshot
Table 121. Merck & Co. Inc.: Product Segments
Table 122. Merck & Co. Inc.: Product Portfolio
Table 123. .Aerie Pharmaceuticals, Inc.: Key Executives
Table 124. .Aerie Pharmaceuticals, Inc.: Company Snapshot
Table 125. .Aerie Pharmaceuticals, Inc.: Product Segments
Table 126. .Aerie Pharmaceuticals, Inc.: Product Portfolio
Table 127. Cipla Ltd.: Key Executives
Table 128. Cipla Ltd.: Company Snapshot
Table 129. Cipla Ltd.: Product Segments
Table 130. Cipla Ltd.: Product Portfolio
List of Figures
Figure 01. Optic Nerve Disorders Treatment Market, 2021-2031
Figure 02. Segmentation of Optic Nerve Disorders Treatment Market, 2021-2031
Figure 03. Top Investment Pockets in Optic Nerve Disorders Treatment Market (2022-2031)
Figure 04. High Bargaining Power of Suppliers
Figure 05. Moderate Bargaining Power of Buyers
Figure 06. High Threat of Substitutes
Figure 07. High Threat of New Entrants
Figure 08. Moderate Intensity of Rivalry
Figure 09. Drivers, Restraints and Opportunities: Globaloptic Nerve Disorders Treatment Market
Figure 10. Optic Nerve Disorders Treatment Market, by Treatment Type, 2021(%)
Figure 11. Comparative Share Analysis of Optic Nerve Disorders Treatment Market for Steroidal Therapy, by Country 2021-2031(%)
Figure 12. Comparative Share Analysis of Optic Nerve Disorders Treatment Market for Immunomodulators Therapy, by Country 2021-2031(%)
Figure 13. Comparative Share Analysis of Optic Nerve Disorders Treatment Market for Others, by Country 2021-2031(%)
Figure 14. Optic Nerve Disorders Treatment Market, by Indication, 2021(%)
Figure 15. Comparative Share Analysis of Optic Nerve Disorders Treatment Market for Glaucoma, by Country 2021-2031(%)
Figure 16. Comparative Share Analysis of Optic Nerve Disorders Treatment Market for Optic Neuritis, by Country 2021-2031(%)
Figure 17. Comparative Share Analysis of Optic Nerve Disorders Treatment Market for Others, by Country 2021-2031(%)
Figure 18. Optic Nerve Disorders Treatment Market, by Distribution Channel, 2021(%)
Figure 19. Comparative Share Analysis of Optic Nerve Disorders Treatment Market for Hospital Pharmacies, by Country 2021-2031(%)
Figure 20. Comparative Share Analysis of Optic Nerve Disorders Treatment Market for Drug Stores and Retail Pharmacies, by Country 2021-2031(%)
Figure 21. Comparative Share Analysis of Optic Nerve Disorders Treatment Market for Online Providers, by Country 2021-2031(%)
Figure 22. Optic Nerve Disorders Treatment Market by Region, 2021
Figure 23. U.S. Optic Nerve Disorders Treatment Market, 2021-2031 ($Million)
Figure 24. Canda Optic Nerve Disorders Treatment Market, 2021-2031 ($Million)
Figure 25. Mexico Optic Nerve Disorders Treatment Market, 2021-2031 ($Million)
Figure 26. Germany Optic Nerve Disorders Treatment Market, 2021-2031 ($Million)
Figure 27. France Optic Nerve Disorders Treatment Market, 2021-2031 ($Million)
Figure 28. UK Optic Nerve Disorders Treatment Market, 2021-2031 ($Million)
Figure 29. Italy Optic Nerve Disorders Treatment Market, 2021-2031 ($Million)
Figure 30. Spain Optic Nerve Disorders Treatment Market, 2021-2031 ($Million)
Figure 31. Rest of Europe Optic Nerve Disorders Treatment Market, 2021-2031 ($Million)
Figure 32. Japan Optic Nerve Disorders Treatment Market, 2021-2031 ($Million)
Figure 33. China Optic Nerve Disorders Treatment Market, 2021-2031 ($Million)
Figure 34. India Optic Nerve Disorders Treatment Market, 2021-2031 ($Million)
Figure 35. Australia Optic Nerve Disorders Treatment Market, 2021-2031 ($Million)
Figure 36. South Korea Optic Nerve Disorders Treatment Market, 2021-2031 ($Million)
Figure 37. Rest of Asia-Pacific Optic Nerve Disorders Treatment Market, 2021-2031 ($Million)
Figure 38. Brazil Optic Nerve Disorders Treatment Market, 2021-2031 ($Million)
Figure 39. Saudi Arabia Optic Nerve Disorders Treatment Market, 2021-2031 ($Million)
Figure 40. South Africa Optic Nerve Disorders Treatment Market, 2021-2031 ($Million)
Figure 41. Rest of LAMEA Optic Nerve Disorders Treatment Market, 2021-2031 ($Million)
Figure 42. Top Winning Strategies, by Year
Figure 43. Top Winning Strategies, by Development
Figure 44. Top Winning Strategies, by Company
Figure 45. Product Mapping of Top 10 Players
Figure 46. Competitive Dashboard
Figure 47. Competitive Heatmap: Optic Nerve Disorders Treatment Market
Figure 48. Top Player Positioning, 2021
Figure 49. Santen Pharmaceutical Co. Ltd.: Net Revenue, 2019-2021 ($Million)
Figure 50. Abbvie Inc.: Net Revenue, 2019-2021 ($Million)
Figure 51. Abbvie Inc.: Revenue Share by Segment, 2021 (%)
Figure 52. Abbvie Inc.: Revenue Share by Region, 2021 (%)
Figure 53. Novartis AG: Net Sales, 2019-2021 ($Million)
Figure 54. Novartis AG: Revenue Share by Segment, 2021 (%)
Figure 55. Novartis AG: Revenue Share by Region, 2021 (%)
Figure 56. Pfizer, Inc.: Net Revenue, 2019-2021 ($Million)
Figure 57. Pfizer, Inc.: Revenue Share by Region, 2021 (%)
Figure 58. Bausch Health Companies, Inc.: Net Sales, 2019-2021 ($Million)
Figure 59. Bausch Health Companies, Inc.: Revenue Share by Segment, 2021 (%)
Figure 60. Bausch Health Companies, Inc.: Revenue Share by Region, 2021 (%)
Figure 61. Teva Pharmaceutical Industries Ltd.: Net Revenue, 2019-2021 ($Million)
Figure 62. Teva Pharmaceutical Industries Ltd.: Revenue Share by Segment, 2021 (%)
Figure 63. Mallinckrodt Pharmaceuticals: Net Sales, 2019-2021 ($Million)
Figure 64. Mallinckrodt Pharmaceuticals: Revenue Share by Segment, 2021 (%)
Figure 65. Mallinckrodt Pharmaceuticals: Revenue Share by Region, 2021 (%)
Figure 66. Merck & Co. Inc.: Net Revenue, 2019-2021 ($Million)
Figure 67. Merck & Co. Inc.: Revenue Share by Segment, 2021 (%)
Figure 68. Merck & Co. Inc.: Revenue Share by Region, 2021 (%)
Figure 69. .Aerie Pharmaceuticals, Inc.: Net Sales, 2019-2021 ($Million)
Figure 70. .Aerie Pharmaceuticals, Inc.: Revenue Share by Segment, 2021 (%)
Figure 71. .Aerie Pharmaceuticals, Inc.: Revenue Share by Region, 2021 (%)
Executive Summary
According to the report titled, 'Optic Nerve Disorders Treatment Market,' the optic nerve disorders treatment market was valued at $3.4 billion in 2021, and is estimated to reach $5.3 billion by 2031, growing at a CAGR of 4.5% from 2022 to 2031.The optic nerve disorder treatment market is likely to experience a significant growth rate of 4.5% from 2022-2031 owing to increasing market demand for optic nerve disorder treatment product from pharmaceuticals sector.
The optic nerve of the eye is the second cranial nerve, which helps transmit sensory information to the brain for vision. During fetal development, this neuron grows from a forebrain optic vesicle. Loss of vision could be caused by damage to the optic nerve or its connections to the brain. Glaucoma, optic nerve atrophy, optic neuritis and others are the most common optic nerve disorders across the globe. glaucoma is the most common type of optic nerve disorder which that damages the optic nerves, which sends images to the brain. The eye’s optic nerve gets damaged due to an increase in the pressure of the eye, which is known as intraocular pressure. Glaucoma is considered as the second largest cause of blindness across the globe. Treatment such steroidal therapy and immunomodulators therapy are the type of treatments use for the optic nerve disorders.
Major factors driving the growth of the optic nerve disorder treatment market include growing awareness about early detection of optic nerve disorders and increase in prevalence of eye disorders. For instance, according to the World Glaucoma Association, it is estimated that 79.6 million individuals will have glaucoma in 2020. This number is likely to increase to 111.8 million individuals in 2040. Moreover, as per the data published by Bright Focus Foundation, in 2019, glaucoma incidences were about 80 million worldwide, expected to reach 111 million by 2040. In addition, increase in technological advancement in optic nerve disorder treatments is the key reason for the growth of the market. Medical imaging, selective laser trabeculoplasty (SLT), optical coherence tomography (OCT), visual fields, micro-invasive glaucoma surgery (MIGS), and progression analysis software are examples of advancement in optometric care that have increased patient preference, thereby boosting the market growth.
Moreover, increase in research and development activities for the manufacturing of immunomodulators for optic nerve disorder treatments along with increase in number of key players has resulted surge in the launch of novel drugs which further boost the market growth. For instance, in February 2021, Santen Pharmaceutical Co., Ltd. and Ube Industries, Ltd. announced the launch of EYBELIS Ophthalmic Solution 0.002% for glaucoma and ocular hypertension treatment in Korea. However, Ophthalmology is a medical specialty, which requires skilled medical professionals to provide quality diagnosis and treatment. There is a lack of skilled and trained professionals in ophthalmology, which can pose a major restraint for the market. Conversely, growth potential of emerging economies that provide lucrative opportunities for the key players in optic nerve disorder treatment market.
The global optic nerve disorder treatment market is segmented on the basis of treatment type, indication, distribution channel and region. As per treatment type, the market is categorized into steroidal therapy, immunomodulators therapy and others. On the basis of indication, it is bifurcated into optic neuritis, glaucoma and others. On the basis of distribution channel, it is segmented into hospital pharmacies, drug stores, retail pharmacies and online providers. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).
The key players profiled in the study includes the AbbVie Inc., Alcon Inc, Bausch Health Companies, Inc., Cipla Ltd., Mallinckrodt pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Santen Pharmaceutical Co., Ltd., Teva pharmaceutical industries ltd. The players in the market have been actively engaged in the adoption strategy such as product approval, product launch and others to remain competitive and gain advantage over the competitors in the market. For instance, In September 2022, Santen Pharmaceutical Co., Ltd. and UBE Corporation announced that the U.S. Food and Drug Administration (FDA) has approved OMLONTI (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. In addition, In March 2021, Teva Pharmaceutical Industries Ltd. announced the launch of the first available generic version of AZOPT (brinzolamide ophthalmic suspension) 1%, approved by the U.S. Food and Drug Administration to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma.
Key Market Insights
- By treatment type, the immunomodulator therapy segment was the highest revenue contributor to the market with a CAGR of 4.6% during the forecast period and is estimated to reach $5028.4 million by 2031.
- Based on indication, glaucoma segment dominates the market in 2021, and is expected to continue this trend during the forecast period.
- Based on distribution channel, the drug stores and retail pharmacies segment dominate the market in 2021, and is expected to continue this trend during the forecast period.
- Based on region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 4.4% during the forecast period
Companies Mentioned
- Santen Pharmaceutical Co., Ltd.
- AbbVie Inc.
- Novartis AG
- Bausch Health Companies, Inc.
- Merck & Co., Inc.
- .Aerie Pharmaceuticals, Inc.
- Cipla Ltd
- mallinckrodt pharmaceuticals
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 257 |
| Published | January 2023 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 3372.46 million |
| Forecasted Market Value ( USD | $ 5247.82 million |
| Compound Annual Growth Rate | 4.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
